EXOZYMES INC.

EXOZYMES INC.

Exozymes Inc. incorporates as a Delaware C-corporation with a narrow, technically demanding mandate: engineering novel enzymes through computational design and laboratory evolution. No corporate website text was available for review at time of writing; the firm maintains a bare domain presence at exozymes.com. Public records indicate the entity has maintained active corporate status without bankruptcy or dissolution filings. The company operates in the industrial biotechnology sector, where enzyme engineering firms typically pursue a capital-light R&D phase followed by licensing agreements with large pharmaceutical or chemical manufacturers. Exozymes Inc. has not disclosed any venture funding rounds, strategic partnerships, or granted patents through USPTO public databases under the exact corporate name as of the most recent review. Team composition and scientific leadership remain opaque. The company has not published a management page, LinkedIn profile, or Crunchbase record. Enzyme engineering startups of this vintage typically originate from principal investigators at research universities — the University of California system, MIT, and ETH Zurich have produced several comparable spinouts — but no specific academic affiliation has been confirmed for Exozymes Inc. No SBIR/STTR grant awards, NIH funding records, or NSF grants appear under this entity name in federal databases. Exozymes Inc. represents the structural phenomenon of the silent-stage biotech: an entity that maintains good standing, secures a domain, and pursues intellectual property development without engaging the standard disclosure machinery of venture capital, academic publishing, or conference presentations. This posture is consistent with a pre-revenue laboratory-stage company operating on founder capital, angel investment, or government research grants that have not been tagged with the corporate entity name in public databases.